On Monday, Eli Lilly And Co (NYSE:LLY) announced results from two Phase 3 studies of mirikizumab across two types of inflammatory bowel diseases (IBD). The studies showed patients treated with mirikizumab sustained stable, long-term remission in ulcerative colitis and Crohn’s disease. Data from the two trials – LUCENT-3 in moderately to severely active ulcerative colitis and VIVID-2 in moderately to severely active Crohn’s disease – will be presented at the American College of Gastroenterology Annual Meeting. Mirikizumab is approved as Omvoh in the U.S. for moderately to severely active ulcera…
